Vol. 3, 2018

Original research papers

Pharmaceutical Sciences


Maja Cvetković, Dušan Ilić, Dušica Stojanović

Pages: 207–212

DOI: 10.21175/RadProc.2018.44

The use of herbal supplements and medicines is increasing rapidly as most people consider them to be of natural origin and therefore safe. Many herbal medications are used to treat diseases but while they are often efficacious, their safety has not sufficiently been considered by physicians or users. One particular safety concern is the risk of interactions with drugs, which often leads to toxicity or loss of therapeutic efficacy. A significant number of patients combine herbal remedies with prescription medications and there is growing evidence for interactions of drugs with herbal remedies or single compound originating from plants. The aim of this paper is to evaluate the possible interactions between chronic patient therapy and herbal substances. The research is presented as a descriptive study which included patients of 30 to 80 years of age, who were randomly selected in Niš from September to December 2017 and agreed to be interviewed as well as completed the questionnaires. We surveyed 157 patients, 115 respondents (73.24%) reported use of dietary supplements. In total, 105 (66.87%) interactions with potential clinical significance were identified. The 5 most common natural products with a potential for interaction (garlic, valerian, ginkgo, and St John’s wort) accounted for 68% of the potential clinically significant interactions. The 4 most common classes of prescription medications with a potential for interaction (antithrombotic medications, sedatives, antidepressant agents, and antidiabetic agents) accounted for 94% of the potential clinically significant interactions. No patient was harmed seriously from any interaction. It is an imperative that pharmacists and doctors ask patients what they are using within their chronic illness treatment and estimate the possible use of a dietary supplement based on the data obtained.
  1. G. K. Dresser, D. G. Bailey, “A basic conceptual and practical overview of interactions with highly prescribed drugs,” Can. J. Clin. Pharmacol., vol. 9, no. 4, pp. 191 – 198, Feb. 2002.
    PMid: 12584577
  2. J. H. Lin, A. Y. Lu, “Inhibition and induction of cytochrome P450 and the clinical implications,” Clin. Pharmacokinet., vol. 35, no. 5, pp. 361 – 390, Nov. 1998.
    DOI: 10.2165/00003088-199835050-00003
    PMid: 9839089
  3. R. M. Goldberg, J. Mabee, L. Chan, S. Wong, “Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population,” Am. J. Emerg., vol. 14, no. 5, pp. 447 – 450, Sep. 1996.
    DOI: 10.1016/S0735-6757(96)90147-3
    PMid: 8765105
  4. M. Shou, “Prediction of pharmacokinetics and drug–drug interactions from in vitro metabolism data,” Curr. Opin. Drug Discov. Dev. Vol. 8, no.1, pp. 66 – 77, Jan. 2005.
    PMid: 15679174
  5. P. B. Watkins, “Drug metabolism by cytochromes P450 in liver and small bowel,” Gastrointest. Pharmacol. vol. 21, no. 3, pp. 511 – 525, Sep.1992
    PMid: 1516957
  6. M. F. Paine et al., “The human intestinal cytochrome P450 pie,” Drug Metabol. Dispos. vol. 34, no. 5, pp. 880 – 886, May 2006.
    DOI: 10.1124/dmd.105.008672
    PMid: 16467132
  7. D. Shaw, G. Ladds, P. Duez, E. Williamson, K. Chan, “Pharmacovigilance of herbal medicine,” J. Ethnopharmacol., vol. 140, no. 3, pp. 513 – 518, Apr. 2012.
    DOI: 10.1016/j.jep.2012.01.051
    PMid: 22342381
  8. H Schilcher, S Kammerer, T Wegener, “Pflanzenprofile,” in Leitfaden Phytoterapie, München, Deutschland: Elsevier GmbH, Urban & Fisher Verlag, 2007, kap. 2. (H Schilcher, S Kammerer, T Wegener, “Plant profiles,” in Phytotherapy Guide, Munich, Germany: Elsevier GmbH, Urban & Fisher Verlag, 2007, ch. 2.)
  9. Z. Bojanic, N. Bojanic, V. Bojanic, “Drug interactions with grapefruit,” Med Pregl. vol. 63, no. 11 – 12, pp. 805 – 810. Nov–Dec. 2010.
    PMid: 21553459
  10. A. De Boer, F. van Hunsel, A. Bast, “Adverse food-drug interactions,” Regul. Toxicol. Pharmacol., vol. 73, no. 3, pp. 859 – 865, Dec. 2015.
    DOI: 10.1016/j.yrtph.2015.10.009
    PMid: 26482404
  11. D. Genser, “Food and drug interaction: consequences for the nutrition/health status,” Ann. Nutr. Metab., vol. 52, suppl. 1, pp. 29 – 32, Mar. 2008.
    DOI: 10.1159/000115345
    PMid: 18382075
  12. B. N. Singh, B. K. Malhotra, “Effects of food on the clinical pharmacokinetics of anticancer agents,” Clin. Pharmacokinet., vol. 43, no. 15, pp. 1127 – 1156, 2004.
    DOI: 10.2165/00003088-200443150-00005
    PMid: 15568891
  13. Ethical principles for medical research involving Human Subjects, World Medical Association, Helsinki, Finland, 1964.
    Retrieved from: https://www.who.int/bulletin/archives/79(4)373.pdf;
    Retrieved on: Jan. 13, 2018
  14. M. Unger, “Pharmacokinetic drug interactions involving Ginkgo biloba,” Drug Metabol. vol. 45, no. 3, pp. 353 – 385, Aug. 2013.
    DOI: 10.3109/03602532.2013.815200
    PMid: 23865865
  15. L. T. Vieira, S. M. Huang, “Botanical-drug interactions: a scientific perspective,” Planta Med. vol. 78, no. 13, pp. 1400 – 1415, Sep. 2012.
    DOI: 10.1055/s-0032-1315145
    PMid: 22864989
  16. M. Cvetkovic, D. Ilic, M. Nikolic, N. Stosic, M. Randjelovic, “Monitoring of the nutritional intake of folic acid among pregnant women in Niš,” Facta Universitatis., vol. 13, no. 3, pp. 239 – 245, 2016.
    DOI: 10.22190/FUWLEP1603239C
  17. D. Stojanovic, D. Markovic, “Nutrigenomika – nauka za 21.vek,” Vojnosanitetski pregled., vol. 68., br. 9, str. 786 – 791, 2011. (D. Stojanovic, D. Markovic, “Nutrigenomics – science for the 21st century,” Military Medical Review, vol. 68, no. 9, pp. 786 – 791, 2011.)
    DOI: 10.2298/VSP1109786S
  18. Interactions by Herb or Supplement, University of Maryland Medical Center, Greenspring (MD), USA, 2007.
    Retrieved from: http://www.umm.edu/altmed/ConsLookups/InteractionsByHerbSupp.html;
    Retrieved on: Jan. 12, 2007
  19. A. Fugh-Berman, “Herb-drug interactions,” Lancet. vol. 355, no. 9198, pp. 134 – 138, Feb. 2000.
    DOI: 10.1016/S0140-6736(99)06457-0
  20. V. Butterweck et al., “Pharmacokinetic herb-drug interactions: are preventive screenings necessary and appropriate,” Planta Med. vol. 70, no. 9, pp. 784 – 791, Sep. 2004.
    DOI: 10.1055/s-2004-827223
    PMid: 15386186
  21. L. Rodriguez-Fragoso et al., “Potential risks resulting from fruit/vegetable-drug interactions: effects on drug-metabolizing enzymes and drug transporters,” J. Food Sci., vol. 76, no. 4, pp. 112 – 124, May 2011.
    DOI: 10.1111/j.1750-3841.2011.02155.x
    PMid: 22417366
  22. E. Nutescu, I. Chuatrisorn, E. Hellenbart, Drug and dietary interactions of warfarin and novel oral anticoagulants: an update, J. Thromb. Thrombolysis.vol. 31, no.3, pp. 326–343. Apr 2011.
    DOI: 10.1007/s11239-011-0561-1
    PMid: 21359645
  23. R. Nowack, “Cytochrome P450 enzyme, and transport protein mediated herb-drug interactions in renal transplant patients: grapefruit juice, St John’s Wort -and beyond!” Nephrology,vol. 13, no. 4, pp. 337 – 347, Jun. 2008.
    DOI: 10.1111/j.1440-1797.2008.00940.x
    PMid: 18363644
  24. J. Boullata, “Natural health product interactions with medication,” Nutr. Clin. Pract., vol. 20, no. 1, pp. 33 – 51, Feb. 2005.
    DOI: 10.1177/011542650502000133
    PMid: 16207645
  25. P. M. Leite, M. A. P. Martins, R. O. Castilho, “Review on mechanisms and interactions in concomitant use of herbs and warfarin therapy,” Biomed. Pharmacother., vol. 83, pp. 14 – 21, Oct. 2016.
    DOI: 10.1016/j.biopha.2016.06.012
  26. E. M. Williamson, S. Driver, K. Baxter, “Stockley’s Herbal Medicines Interactions: A Guide to the Interactions of Herbal Medicines. Second ed.,” Pharmaceutical Press, vol. 102, no. 3, pp. 221 – 222, Jul. 2014.
    DOI: 10.3163/1536-5050.102.3.018
    PMCid: PMC4076137
  27. D. M. Qato et al., “Use of prescription and over the counter medications and dietary supplements among older adults in the United States,” JAMA., vol. 300, no. 24, pp. 2867 – 2878, Dec. 2008.
    DOI: 10.1001/jama.2008.89
    PMid: 19109115
  28. Drugs, Herbs and Supplements,NIH MedlinePlus, Bethesda (MD), USA, 2007.
    Retrieved from: https://medlineplus.gov/druginformation.html;
    Retrieved on: Jun. 14, 2018
  29. J. P. Gonzalez et al., “Influence of vitamin C on the absorption and first pass metabolism of propranolol,” Eur. J. Clin. Pharmacol., vol. 48, no. 3-4. pp. 295 – 297, Jul. 1995.
    DOI: 10.1007/BF00198315
    PMid: 7589058